From the recent call, ALLO have disclosed they are already designing next-gen TurboCARs to overcome immunosuppressive TMEs, particularly in solid tumours by engineering T-cell stimulatory domains that are activated by certain factors, such as PD-L1 and TGFb. Also, in concert with Baylor College of Medicine, are exploring the use of alloimmune defense receptors (to overcome rejection) [1].
Other planned improvements include manufacturing and CAR engineering. On top of this, there are twelve solid tumour targets, with two (CD70 [2,3] and DLL3 [4,5]) disclosed.
Market Data 
Markets 
AI
